Back to Results
First PageMeta Content
Intersect ENT / Propel mometasone furoate implant / Forward-looking statement / Otorhinolaryngology / Sinusitis / Thoratec


Intersect ENT Appoints David Lehman General Counsel MENLO PARK, Calif., February 22, 2016 – Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat
Add to Reading List

Open Document

File Size: 99,40 KB

Share Result on Facebook